Cargando…

Comparative Efficacy of Guanfacine Extended Release Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: Applying Matching-Adjusted Indirect Comparison Methodology

BACKGROUND: No head-to-head clinical trials have been published comparing guanfacine extended release (GXR) and atomoxetine (ATX): two nonstimulants approved for the treatment of attention-deficit/hyperactivity disorder (ADHD). However, other study designs or methods could be used to indirectly comp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sikirica, Vanja, Findling, Robert L., Signorovitch, James, Erder, M. Haim, Dammerman, Ryan, Hodgkins, Paul, Lu, Mei, Xie, Jipan, Wu, Eric Q.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2013
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3824845/ https://www.ncbi.nlm.nih.gov/pubmed/23975660 http://dx.doi.org/10.1007/s40263-013-0102-x

Ejemplares similares

Authors’ Reply to Alatorre et al.: “Cost Effectiveness of Guanfacine Extended-Release Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder: Application of a Matching-Adjusted Indirect Comparison”
por: Erder, M. Haim, et al.
Publicado: (2013)

Cost Effectiveness of Guanfacine Extended Release as an Adjunctive Therapy to a Stimulant Compared with Stimulant Monotherapy for the Treatment of Attention-Deficit Hyperactivity Disorder in Children and Adolescents
por: Sikirica, Vanja, et al.
Publicado: (2012)

Comparative efficacy and safety of attention-deficit/hyperactivity disorder pharmacotherapies, including guanfacine extended release: a mixed treatment comparison
por: Joseph, Alain, et al.
Publicado: (2017)

Concomitant Pharmacotherapy of Psychotropic Medications in EU Children and Adolescents with Attention-Deficit/Hyperactivity Disorder
por: Sikirica, Vanja, et al.
Publicado: (2013)

Guanfacine extended release for children and adolescents with attention-deficit/hyperactivity disorder: efficacy following prior methylphenidate treatment
por: Huss, Michael, et al.
Publicado: (2016)

Preferences for Attention-Deficit/Hyperactivity Disorder (ADHD) Non-Stimulant Treatment Characteristics Among Children and Adolescents With ADHD and Their Caregivers
por: Flood, Emuella, et al.
Publicado: (2016)

Comparative Treatment Patterns, Resource Utilization, and Costs in Stimulant-Treated Children with ADHD Who Require Subsequent Pharmacotherapy with Atypical Antipsychotics Versus Non-Antipsychotics
por: Sikirica, Vanja, et al.
Publicado: (2012)

Does Guanfacine Extended Release Impact Functional Impairment in Children with Attention-Deficit/Hyperactivity Disorder? Results from a Randomized Controlled Trial
por: Stein, Mark A., et al.
Publicado: (2015)

Is adjunctive pharmacotherapy in attention-deficit/hyperactivity disorder cost-effective in Canada: a cost-effectiveness assessment of guanfacine extended-release as an adjunctive therapy to a long-acting stimulant for the treatment of ADHD
por: Lachaine, Jean, et al.
Publicado: (2016)

Caregiver perspective on pediatric attention-deficit/hyperactivity disorder: medication satisfaction and symptom control
por: Fridman, Moshe, et al.
Publicado: (2017)

Treatment outcomes after methylphenidate in adults with attention-deficit/hyperactivity disorder treated with lisdexamfetamine dimesylate or atomoxetine
por: Joseph, Alain, et al.
Publicado: (2016)

Unmet Needs Associated with Attention-Deficit/Hyperactivity Disorder in Eight European Countries as Reported by Caregivers and Adolescents: Results from Qualitative Research
por: Sikirica, Vanja, et al.
Publicado: (2014)

Profile of guanfacine extended release and its potential in the treatment of attention-deficit hyperactivity disorder
por: Martinez-Raga, Jose, et al.
Publicado: (2015)

Extended-Release Viloxazine Compared with Atomoxetine for Attention Deficit Hyperactivity Disorder
por: Price, Maxwell Z., et al.
Publicado: (2023)

Psychometric validation of the Weiss Functional Impairment Rating Scale-Parent Report Form in children and adolescents with attention-deficit/hyperactivity disorder
por: Gajria, Kavita, et al.
Publicado: (2015)

Comparative treatment patterns, healthcare resource utilization and costs of atomoxetine and long-acting methylphenidate among children and adolescents with attention-deficit/hyperactivity disorder in Germany
por: Greven, Peter, et al.
Publicado: (2016)

Adherence, persistence, and medication discontinuation in patients with attention-deficit/hyperactivity disorder – a systematic literature review
por: Gajria, Kavita, et al.
Publicado: (2014)

Psychostimulants Modafinil, Atomoxetine and Guanfacine Impair Bone Cell Differentiation and MSC Migration
por: Wagener, Nele, et al.
Publicado: (2022)

Effect of Atomoxetine on Hyperactivity in an Animal Model of Attention-Deficit/Hyperactivity Disorder (ADHD)
por: Moon, Su Jin, et al.
Publicado: (2014)

Functional outcomes from a head-to-head, randomized, double-blind trial of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder and an inadequate response to methylphenidate
por: Nagy, Peter, et al.
Publicado: (2015)

Relationship between symptom impairment and treatment outcome in children and adolescents with attention-deficit/hyperactivity disorder: a physician perspective
por: Setyawan, Juliana, et al.
Publicado: (2014)

A Cost-Utility Analysis of Lisdexamfetamine Versus Atomoxetine in the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder and Inadequate Response to Methylphenidate
por: Zimovetz, Evelina A., et al.
Publicado: (2016)

Authors’ Reply to Pande et al. Comment on “Extended-Release Viloxazine Compared to Atomoxetine for Attention Deficit Hyperactivity Disorder”
por: Price, Maxwell Z., et al.
Publicado: (2023)

Economic impact of childhood/adolescent ADHD in a European setting: the Netherlands as a reference case
por: Le, Hoa H., et al.
Publicado: (2013)

Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: a review
por: Hammerness, Paul, et al.
Publicado: (2009)

Atomoxetine for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children with ADHD and dyslexia
por: Sumner, Calvin R, et al.
Publicado: (2009)

Efficacy and Safety of Atomoxetine in the Treatment of Children and Adolescents with Attention Deficit Hyperactivity Disorder
por: Kohn, Michael R., et al.
Publicado: (2012)

Real‐World Dosing Patterns of Atomoxetine in Adults with Attention‐Deficit/Hyperactivity Disorder
por: Kabul, Samaneh, et al.
Publicado: (2015)

Atomoxetine-Associated Eyebrow Alopecia in a Girl With Attention-Deficit/Hyperactivity Disorder
por: Zhang, Ying, et al.
Publicado: (2021)

Identification of factors associated with the efficacy of atomoxetine in adult attention‐deficit/hyperactivity disorder
por: Nagai, Tsutomu, et al.
Publicado: (2022)

Safety and efficacy of guanfacine extended-release in adults with attention-deficit/hyperactivity disorder: an open-label, long-term, phase 3 extension study
por: Iwanami, Akira, et al.
Publicado: (2020)

Attention deficits following ADEM ameliorated by guanfacine
por: Singh-Curry, Victoria, et al.
Publicado: (2010)

Correction to: Safety and efficacy of guanfacine extended-release in adults with attention-deficit/hyperactivity disorder: an open-label, long-term, phase 3 extension study
por: Iwanami, Akira, et al.
Publicado: (2020)

Pharmacokinetics of Coadministration of Guanfacine Extended Release and Methylphenidate Extended Release
por: Roesch, Benno, et al.
Publicado: (2013)

Treatment Response and Remission in a Double-Blind, Randomized, Head-to-Head Study of Lisdexamfetamine Dimesylate and Atomoxetine in Children and Adolescents with Attention-Deficit Hyperactivity Disorder
por: Dittmann, Ralf W., et al.
Publicado: (2014)

Efficacy and Safety of Lisdexamfetamine Dimesylate and Atomoxetine in the Treatment of Attention-Deficit/Hyperactivity Disorder: a Head-to-Head, Randomized, Double-Blind, Phase IIIb Study
por: Dittmann, Ralf W., et al.
Publicado: (2013)

Factors associated with caregiver burden among pharmacotherapy-treated children/adolescents with ADHD in the Caregiver Perspective on Pediatric ADHD survey in Europe
por: Fridman, Moshe, et al.
Publicado: (2017)

Pharmacokinetics of Coadministered Guanfacine Extended Release and Lisdexamfetamine Dimesylate
por: Roesch, Benno, et al.
Publicado: (2013)

Comparative efficacy of methylphenidate and atomoxetine in oppositional defiant disorder comorbid with attention deficit hyperactivity disorder
por: Garg, Jasmin, et al.
Publicado: (2015)

Atomoxetine Induced Hypomania in a Patient with Bipolar Disorder and Adult Attention Deficit Hyperactivity Disorder
por: Kumar, Vijaya, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_fc2i4c9v4j29qoe4avkvasaj7j